These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21940371)

  • 1. Results of a phase 4 trial of Tacrobell® in liver transplantation patients: a multicenter study in South Korea.
    Yu YD; Lee SG; Joh JW; Kwon CH; Kim DG; Suh KS; Lee NJ; Hwang S; Ahn CS; Kim KH; Moon DB; Ha TY; Song GW; Jung DH
    Hepatogastroenterology; 2012; 59(114):357-63. PubMed ID: 21940371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 39-month follow-up study to evaluate the safety and efficacy in kidney transplant recipients treated with modified-release tacrolimus (FK506E)-based immunosuppression regimen.
    Han DJ; Park JB; Kim YS; Kim SJ; Ha J; Kim HC; Kim SJ; Moon IS; Yang CW
    Transplant Proc; 2012 Jan; 44(1):115-7. PubMed ID: 22310592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 6-month, multicenter, single-arm pilot study to evaluate the efficacy and safety of generic tacrolimus (TacroBell) after primary renal transplantation.
    Kim SJ; Huh KH; Han DJ; Moon IS; Kim SJ; Kim YL; Kim HC; Lee S; Kang CM; Cho BH; Kim YS
    Transplant Proc; 2009 Jun; 41(5):1671-4. PubMed ID: 19545705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients.
    Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY
    Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of early corticosteroid withdrawal on graft survival in liver transplant recipients.
    Meadows HB; Taber DJ; Pilch NA; Tischer SM; Baliga PK; Chavin KD
    Transplant Proc; 2012 Jun; 44(5):1323-8. PubMed ID: 22664009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
    Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of twice-daily to once-daily tacrolimus is safe in stable adult living donor liver transplant recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):374-9. PubMed ID: 26256081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up.
    Jonas S; Neuhaus R; Junge G; Klupp J; Theruvat T; Langrehr JM; Settmacher U; Neuhaus P
    Int Immunopharmacol; 2005 Jan; 5(1):125-8. PubMed ID: 15589470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the long-term efficacy and safety of generic tacrolimus, Tacrobell, with Prograf in liver transplant recipients.
    Choi HJ; Kim DG; Kwak BJ; Han JH; Hong TH; You YK
    Drug Des Devel Ther; 2018; 12():295-301. PubMed ID: 29483770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeating intraportal donor-specific transfusion may induce tolerance following adult living-related donor liver transplantation.
    Sato Y; Ichida T; Watanabe H; Yamamoto S; Oya H; Nakatsuka H; Kobayashi T; Watanabe T; Kameyama H; Hatakeyama K
    Hepatogastroenterology; 2003; 50(51):601-6. PubMed ID: 12828042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of cyclosporine microemulsion and tacrolimus in 39 recipients of living donor liver transplantation.
    Tanaka K; Lake J; Villamil F; Levy G; Marotta P; Mies S; de Hemptinne B; Moench C
    Liver Transpl; 2005 Nov; 11(11):1395-402. PubMed ID: 16237691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcome of unrelated donor bone marrow transplantation in patients with hematologic malignancies using tacrolimus (FK506) and low dose methotrexate for graft-versus-host disease prophylaxis.
    Devine SM; Geller RB; Lin LB; Dix SP; Holland HK; Maurer D; O'Toole K; Keller J; Connaghan DG; Heffner LT; Hillyer CD; Rodey GE; Winton EF; Maher RM; Fitzsimmons WE; Wingard JR
    Biol Blood Marrow Transplant; 1997 Apr; 3(1):25-33. PubMed ID: 9209738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open, randomized, multicenter clinical trial of oral tacrolimus in liver allograft transplantation: a comparison of dual vs. triple drug therapy.
    González MG; Madrazo CP; Rodríguez AB; Gutiérrez MG; Herrero JI; Pallardó JM; Ortiz de Urbina J; Paricio PP
    Liver Transpl; 2005 May; 11(5):515-24. PubMed ID: 15838889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.
    Greig P; Lilly L; Scudamore C; Erb S; Yoshida E; Kneteman N; Bain V; Ghent C; Marotta P; Grant D; Wall W; Tchervenkov J; Barkun J; Roy A; Marleau D; McAlister V; Peltekian K
    Liver Transpl; 2003 Jun; 9(6):587-95. PubMed ID: 12783400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of steroid-free immunosuppression with tacrolimus and daclizumab in liver transplant recipients: 6-year follow-up in a single center.
    Foroncewicz B; Mucha K; Ryszkowska E; Ciszek M; Ziółkowski J; Porowski D; Krawczyk M; Paczek L
    Transplant Proc; 2009 Oct; 41(8):3103-6. PubMed ID: 19857686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can daclizumab reduce acute rejection and improve long-term renal function in tacrolimus-based primary renal transplant recipients?
    Cheung CY; Liu YL; Wong KM; Chan HW; Chan YH; Wong HS; Chak WL; Choi KS; Chau KF; Shek CC; Li CS
    Nephrology (Carlton); 2008 Jun; 13(3):251-5. PubMed ID: 18221256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Early Conversion From Prograf to Generic Tacrolimus in Adult Living Donor Liver Transplant Recipients.
    Kim SH; Lee SD; Kim YK; Park SJ
    Transplant Proc; 2015; 47(6):1915-6. PubMed ID: 26293073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High tacrolimus intra-patient variability is associated with graft rejection, and
    Del Bello A; Congy-Jolivet N; Danjoux M; Muscari F; Lavayssière L; Esposito L; Hebral AL; Bellière J; Kamar N
    World J Gastroenterol; 2018 Apr; 24(16):1795-1802. PubMed ID: 29713132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of immunosuppressive therapy based on a multiparametric mixed lymphocyte reaction assay reduces infectious complications and mortality in living donor liver transplant recipients.
    Tanaka Y; Tashiro H; Onoe T; Ide K; Ishiyama K; Ohdan H
    Transplant Proc; 2012 Mar; 44(2):555-9. PubMed ID: 22410068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.